Pre Exposure Prophylaxis News and Research

RSS

Oral tenofovir discontinued in HIV clinical trial

A large-scale clinical trial evaluating whether daily use of an oral tablet or vaginal gel containing antiretroviral drugs can prevent HIV infection in women is being modified because an interim review found that the study cannot show that one of the study products, oral tenofovir, marketed under the trade name Viread, is effective.

29 Sep 2011

VOICE HIV prevention trial to discontinue use of tenofovir tablets

VOICE, an HIV prevention trial evaluating two antiretroviral (ARV)-based approaches for preventing the sexual transmission of HIV in women - daily use of one of two different ARV tablets or of a vaginal gel - will be dropping one of the oral tablets from the study.

29 Sep 2011

FDA denies FOIA regarding Gilead Sciences' Truvada correspondence, AHF sues

AIDS Healthcare Foundation (AHF) today filed a lawsuit against the Food and Drug Administration (FDA) over its denial of AHF's Freedom of Information Act (FOIA) requests regarding correspondence between the FDA and Gilead Sciences regarding its potential application to the FDA to expand the use of its AIDS drug, Truvada, for use as an HIV prevention pill for pre-exposure prophylaxis (PrEP) in uninfected individuals.

23 Sep 2011

Forum for Collaborative HIV Research discusses PrEP

Following an August 19 meeting convened by the Forum for Collaborative HIV Research to explore recent findings showing the success of pre-exposure prophylaxis (PrEP), "conference participants urged healthcare providers and the public to await further guidance from the CDC and FDA before considering using PrEP. However, if providers believe that initiating PrEP is urgent for a specific patient, CDC recommends following the cautions and procedures previously published for PrEP use in MSM", a Forum press release states.

26 Aug 2011

AHF shares The Lancet's concerns over use of Gilead's Truvada as HIV prevention pill

Today AIDS Healthcare Foundation (AHF) commented on an editorial published in the September 2011 issue of The Lancet Infectious Diseases that raises concerns about the use of the HIV treatment drug Truvada, manufactured by Gilead Sciences Inc., as an HIV prevention pill or pre-exposure prophylaxis (PrEP), agreeing with the publication's public health concerns.

25 Aug 2011

AHF: Gilead's campaign for FDA approval of Truvada leads to black marketing in Florida

Today AIDS Healthcare Foundation (AHF) decried the fact that the recent campaign by Gilead Sciences Inc. to obtain approval by the U.S. Food & Drug Administration for Truvada as PrEP (pre-exposure prophylaxis) has led to a "black market" for the drug in Florida.

20 Aug 2011

PrEP raises questions regarding 'risk disinhibition' and drug resistance

Nature News reports on "the possibility of unintended public-health consequences" of pre-exposure prophylaxis (PrEP) for HIV and pharmaceutical company Gilead's plan to ask the FDA to evaluate its combination antiretroviral (ARV) drug Truvada for use in healthy people.

18 Aug 2011

IAS conference concludes with positive news on HIV prevention

"Scientists on Wednesday wrapped up their biggest forum in the 30-year history of AIDS, unveiling stunning weapons to prevent the spread of HIV," Agence France-Presse reports about the 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Rome.

22 Jul 2011

UNC receives $3M federal grant for AIDS research

Scientists at the University of North Carolina at Chapel Hill schools of medicine and pharmacy have been awarded a $3 million federal grant to develop and test a new generation of treatments aimed at preventing sexual transmission of HIV to uninfected individuals.

19 Jul 2011

Novel approach for preventing HIV infection

Scientists at Osel Inc. and the National Cancer Institute (NCI) have developed a new way to prevent HIV infection by genetically enhancing the ability of naturally occurring vaginal bacteria to block viral transmission.

19 Jul 2011

Shah congratulates researchers on PrEP findings

In statement released Thursday, USAID Administrator Rajiv Shah said, "I congratulate the Partners PrEP and CDC TDF2 teams on their study findings demonstrating that PrEP (pre-exposure prophylaxis) - and HIV medication when taken orally, once a day - is highly effective in preventing HIV in heterosexual men and women.

16 Jul 2011

Two new studies support use of PrEP for HIV prevention among heterosexual men and women

"Two new studies done in three African countries have shown for the first time that AIDS drugs taken daily can cut by more than half a person's chance of becoming infected with HIV through heterosexual intercourse," the Washington Post reports.

14 Jul 2011

Pre-exposure prophylaxis reduces risk of HIV infection

In a result that will fundamentally change approaches to HIV prevention in Africa, an international study has demonstrated that individuals at high risk for HIV infection who took a daily tablet containing an HIV medication - either the antiretroviral medication tenofovir or tenofovir in combination with emtricitabine - experienced significantly fewer HIV infections than those who received a placebo pill.

14 Jul 2011

Daily pill ‘combo’ prevents HIV transmission: New African study

According two studies in Africa, taking a daily pill containing either one or two anti-HIV drugs can reduce transmission of the virus by as much as three-quarters among heterosexual couples. This is an encouraging finding that could help focus on AIDS prevention. The results were so compelling that the larger study was halted early and the drugs given to all the participants, researchers said Wednesday.

13 Jul 2011

Physicians urge FDA not to approve Truvada as an HIV prevention pill

Last week, a group of 55 U.S. physicians sent a letter to the U.S. Food & Drug Administration (FDA), urging the agency not to approve the use of Gilead's HIV/AIDS treatment drug Truvada for use as an HIV prevention pill - also known as "pre-exposure prophylaxis" (PrEP).

30 Jun 2011

International coalition launches common platform to end AIDS epidemic

An international coalition of scientists and activists today launched a common platform for ending the AIDS epidemic. Thirty years into the epidemic, as world leaders come together at the United Nations to recommit to a global AIDS response, the broad-based international coalition issued a statement calling for world leaders to support a rational, evidence-based approach to responding to AIDS.

8 Jun 2011

Study assesses public's willingness to consider pre-exposure prophylaxis for HIV prevention

In a recent clinical trial, non-HIV-infected individuals who used the antiretroviral drug Truvada on a daily basis cut their risk of becoming infected with HIV by 44 percent.

4 Jun 2011

NIH scientists discuss expanded HIV testing and new prevention tools

In the 30 years since the first reported cases of a mysterious illness now known as AIDS, researchers have made extraordinary advances in understanding, treating and preventing the disease.

1 Jun 2011

'No magic pill' for HIV prevention

AIDS Healthcare Foundation today released the results of a groundbreaking online survey designed to gain better understanding of community perceptions regarding the possible use of an HIV prevention pill.

20 May 2011

AVAC calls on donors, policy makers to strengthen support for AIDS vaccine research

This year HIV Vaccine Awareness Day comes at the dawn of a true prevention revolution that could finally turn the tide of the AIDS epidemic. AIDS vaccine research is a critical part of that revolution and on this day AVAC calls on donors, policy makers and others to strengthen support for AIDS vaccine research.

19 May 2011